These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31036650)

  • 1. Molecular engineering of an efficient four-domain DAF-MCP chimera reveals the presence of functional modularity in RCA proteins.
    Panwar HS; Ojha H; Ghosh P; Barage SH; Raut S; Sahu A
    Proc Natl Acad Sci U S A; 2019 May; 116(20):9953-9958. PubMed ID: 31036650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Domain swapping reveals complement control protein modules critical for imparting cofactor and decay-accelerating activities in vaccinia virus complement control protein.
    Ahmad M; Raut S; Pyaram K; Kamble A; Mullick J; Sahu A
    J Immunol; 2010 Nov; 185(10):6128-37. PubMed ID: 20956343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein.
    Kim YU; Kinoshita T; Molina H; Hourcade D; Seya T; Wagner LM; Holers VM
    J Exp Med; 1995 Jan; 181(1):151-9. PubMed ID: 7528766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of complement regulatory domains in vaccinia virus complement control protein.
    Mullick J; Bernet J; Panse Y; Hallihosur S; Singh AK; Sahu A
    J Virol; 2005 Oct; 79(19):12382-93. PubMed ID: 16160165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational analysis of Kaposica reveals that bridging of MG2 and CUB domains of target protein is crucial for the cofactor activity of RCA proteins.
    Gautam AK; Panse Y; Ghosh P; Reza MJ; Mullick J; Sahu A
    Proc Natl Acad Sci U S A; 2015 Oct; 112(41):12794-9. PubMed ID: 26420870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
    Iwata K; Seya T; Ariga H; Nagasawa S
    J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.
    Lublin DM; Coyne KE
    J Exp Med; 1991 Jul; 174(1):35-44. PubMed ID: 1711565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Separation of decay-accelerating and cofactor functional activities of Kaposi's sarcoma-associated herpesvirus complement control protein using monoclonal antibodies.
    Mark L; Proctor DG; Blackbourn DJ; Blom AM; Spiller OB
    Immunology; 2008 Feb; 123(2):228-38. PubMed ID: 17764451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional properties of membrane cofactor protein of complement.
    Seya T; Atkinson JP
    Biochem J; 1989 Dec; 264(2):581-8. PubMed ID: 2481448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack.
    Brodbeck WG; Mold C; Atkinson JP; Medof ME
    J Immunol; 2000 Oct; 165(7):3999-4006. PubMed ID: 11034410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of electrostatics on the complement regulatory functions of Kaposica, the complement inhibitor of Kaposi's sarcoma-associated herpesvirus.
    Pyaram K; Kieslich CA; Yadav VN; Morikis D; Sahu A
    J Immunol; 2010 Feb; 184(4):1956-67. PubMed ID: 20089702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Structure and function of a cell-associated complement regulatory protein, membrane cofactor protein (MCP)].
    Seya T
    Hokkaido Igaku Zasshi; 1988 Mar; 63(2):259-68. PubMed ID: 3384397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode.
    Forneris F; Wu J; Xue X; Ricklin D; Lin Z; Sfyroera G; Tzekou A; Volokhina E; Granneman JC; Hauhart R; Bertram P; Liszewski MK; Atkinson JP; Lambris JD; Gros P
    EMBO J; 2016 May; 35(10):1133-49. PubMed ID: 27013439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation.
    Kavanagh D; Burgess R; Spitzer D; Richards A; Diaz-Torres ML; Goodship JA; Hourcade DE; Atkinson JP; Goodship TH
    Mol Immunol; 2007 May; 44(12):3162-7. PubMed ID: 17368771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping of functional domains in herpesvirus saimiri complement control protein homolog: complement control protein domain 2 is the smallest structural unit displaying cofactor and decay-accelerating activities.
    Singh AK; Yadav VN; Pyaram K; Mullick J; Sahu A
    J Virol; 2009 Oct; 83(19):10299-304. PubMed ID: 19640995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergy between two active sites of human complement receptor type 1 (CD35) in complement regulation: implications for the structure of the classical pathway C3 convertase and generation of more potent inhibitors.
    Krych-Goldberg M; Hauhart RE; Porzukowiak T; Atkinson JP
    J Immunol; 2005 Oct; 175(7):4528-35. PubMed ID: 16177096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric CD46/DAF molecules reveal a cryptic functional role for SCR1 of DAF in regulating complement activation.
    Christiansen D; Loveland B; Kyriakou P; Lanteri M; Rubinstein E; Gerlier D
    Mol Immunol; 2000; 37(12-13):687-96. PubMed ID: 11275254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the active sites in decay-accelerating factor.
    Kuttner-Kondo LA; Mitchell L; Hourcade DE; Medof ME
    J Immunol; 2001 Aug; 167(4):2164-71. PubMed ID: 11490001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Kaposi's sarcoma-associated herpesvirus complement control protein mimics human molecular mechanisms for inhibition of the complement system.
    Mark L; Lee WH; Spiller OB; Proctor D; Blackbourn DJ; Villoutreix BO; Blom AM
    J Biol Chem; 2004 Oct; 279(43):45093-101. PubMed ID: 15304516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCP1-4 of the C4b-binding protein alpha-chain are required for factor I mediated cleavage of complement factor C3b.
    Blom AM; Kask L; Dahlbäck B
    Mol Immunol; 2003 Jan; 39(10):547-56. PubMed ID: 12431388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.